{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:51:30Z","timestamp":1789026690257,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11095-014-1581-2","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T16:51:44Z","timestamp":1417539104000},"page":"1864-1883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach"],"prefix":"10.1007","volume":"32","author":[{"given":"Nikolaos","family":"Tsamandouras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Rostami-Hodjegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Galetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Aarons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,2]]},"reference":[{"issue":"3","key":"1581_CR1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00003088-199324030-00002","volume":"24","author":"VF Mauro","year":"1993","unstructured":"Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet. 1993;24(3):195\u2013202.","journal-title":"Clin Pharmacokinet"},{"issue":"9326","key":"1581_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"R Collins","year":"2002","unstructured":"Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet"},{"issue":"2","key":"1581_CR3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0090-9556(25)07595-6","volume":"18","author":"S Vickers","year":"1990","unstructured":"Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos. 1990;18(2):138\u201345.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1581_CR4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s11095-005-6037-2","volume":"22","author":"T Prueksaritanont","year":"2005","unstructured":"Prueksaritanont T, Qiu Y, Mu L, Michel K, Brunner J, Richards KM, et al. Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. Pharm Res. 2005;22(7):1101\u20139.","journal-title":"Pharm Res"},{"issue":"5","key":"1581_CR5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","volume":"30","author":"T Prueksaritanont","year":"2002","unstructured":"Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002;30(5):505\u201312.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1581_CR6","first-page":"1191","volume":"25","author":"T Prueksaritanont","year":"1997","unstructured":"Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997;25(10):1191\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1581_CR7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1365-2125.2003.01833.x","volume":"56","author":"T Prueksaritanont","year":"2003","unstructured":"Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol. 2003;56(1):120\u20134.","journal-title":"Br J Clin Pharmacol"},{"key":"1581_CR8","author":"LB Ramsey","year":"2014","unstructured":"Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014. doi: 10.1038\/clpt.2014.125 [advance online publication].","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1581_CR9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/clpt.2014.55","volume":"96","author":"N Tsamandouras","year":"2014","unstructured":"Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, et al. Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clin Pharmacol Ther. 2014;96(1):90\u2013100.","journal-title":"Clin Pharmacol Ther"},{"key":"1581_CR10","author":"N Tsamandouras","year":"2013","unstructured":"Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the \u201cbottom-up\u201d and \u201ctop-down\u201d approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. 2013. doi: 10.1111\/bcp.12234 .","journal-title":"Br J Clin Pharmacol"},{"key":"1581_CR11","first-page":"e121","volume":"3","author":"TA Leil","year":"2014","unstructured":"Leil TA. A Bayesian perspective on estimation of variability and uncertainty in mechanism-based models. CPT: Pharmacosmet Syst Pharmacol. 2014;3:e121.","journal-title":"CPT: Pharmacosmet Syst Pharmacol"},{"issue":"5","key":"1581_CR12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1023\/A:1022972420004","volume":"29","author":"PO Gisleskog","year":"2002","unstructured":"Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29(5):473\u2013505.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"1581_CR13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00228-007-0264-x","volume":"63","author":"G Langdon","year":"2007","unstructured":"Langdon G, Gueorguieva I, Aarons L, Karlsson M. Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM. Eur J Clin Pharmacol. 2007;63(5):485\u201398.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1581_CR14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1581_CR15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand M, Karlsson M. Handling data below the limit of quantification in mixed effect models. AAPS J. 2009;11(2):371\u201380.","journal-title":"AAPS J"},{"key":"1581_CR16","volume-title":"NONMEM users guide - part VIII, help guide","author":"AJ Boeckman","year":"2011","unstructured":"Boeckman AJ, Sheiner LB, Beal SL. NONMEM users guide - part VIII, help guide. Ellicott City: ICON Development Solutions; 2011."},{"issue":"4","key":"1581_CR17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/10543400802071360","volume":"18","author":"A Dokoumetzidis","year":"2008","unstructured":"Dokoumetzidis A, Aarons L. Analytical expressions for combining population pharmacokinetic parameters from different studies. J Biopharm Stat. 2008;18(4):662\u201376.","journal-title":"J Biopharm Stat"},{"issue":"12","key":"1581_CR18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","volume":"16","author":"MK Pasanen","year":"2006","unstructured":"Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16(12):873\u20139.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"1581_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1581_CR20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/clpt.2012.68","volume":"92","author":"P Zhao","year":"2012","unstructured":"Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther. 2012;92(1):17\u201320.","journal-title":"Clin Pharmacol Ther"},{"key":"1581_CR21","first-page":"e101","volume":"3","author":"B Agoram","year":"2014","unstructured":"Agoram B. Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models. CPT: Pharmacosmet Syst Pharmacol. 2014;3:e101.","journal-title":"CPT: Pharmacosmet Syst Pharmacol"},{"issue":"6","key":"1581_CR22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/00498254.2012.739719","volume":"43","author":"JW Polli","year":"2013","unstructured":"Polli JW, Hussey E, Bush M, Generaux G, Smith G, Collins D, et al. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. Xenobiotica. 2013;43(6):498\u2013508.","journal-title":"Xenobiotica"},{"issue":"5","key":"1581_CR23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejps.2009.12.002","volume":"39","author":"K Rowland Yeo","year":"2010","unstructured":"Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut\u2014the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci. 2010;39(5):298\u2013309.","journal-title":"Eur J Pharm Sci"},{"key":"1581_CR24","doi-asserted-by":"crossref","unstructured":"Gertz M, Tsamandouras N, Sall C, Houston JB, Galetin A. Reduced physiologically-based pharmacokinetic model of repaglinide: Impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. Pharm Res. 2014;31(9):2367-82.","DOI":"10.1007\/s11095-014-1333-3"},{"issue":"3","key":"1581_CR25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","volume":"63","author":"PJ Neuvonen","year":"1998","unstructured":"Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63(3):332\u201341.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1581_CR26","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","volume":"94","author":"TA Jacobson","year":"2004","unstructured":"Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140\u20136.","journal-title":"Am J Cardiol"},{"issue":"2","key":"1581_CR27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2133\/dmpk.DMPK-13-RG-053","volume":"29","author":"H Son","year":"2014","unstructured":"Son H, Lee D, Lim LA, Jang SB, Roh H, Park K. Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine. Drug Metab Pharmacokinet. 2014;29(2):120\u20138.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"1581_CR28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/dmd.30.5.488","volume":"30","author":"T Satoh","year":"2002","unstructured":"Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, Du BNL. Current progress on esterases: from molecular structure to function. Drug Metab Dispos. 2002;30(5):488\u201393.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"1581_CR29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00044011-200121090-00006","volume":"21","author":"TB Vree","year":"2001","unstructured":"Vree TB, Dammers E, Ulc I, Horkovics-Kovats S, Ryska M, Merkx I. Variable plasma\/liver and tissue esterase hydrolysis of simvastatin in healthy volunteers after a single oral dose. Clin Drug Invest. 2001;21(9):643\u201352.","journal-title":"Clin Drug Invest"},{"issue":"7","key":"1581_CR30","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s11095-007-9519-6","volume":"25","author":"M Tubic-Grozdanis","year":"2008","unstructured":"Tubic-Grozdanis M, Hilfinger J, Amidon G, Kim J, Kijek P, Staubach P, et al. Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms. Pharm Res. 2008;25(7):1591\u2013600.","journal-title":"Pharm Res"},{"issue":"1","key":"1581_CR31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10928-011-9228-y","volume":"39","author":"L Gibiansky","year":"2012","unstructured":"Gibiansky L, Gibiansky E, Bauer R. Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model. J Pharmacokinet Pharmacodyn. 2012;39(1):17\u201335.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"1581_CR32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","volume":"106","author":"MJ Knauer","year":"2010","unstructured":"Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010;106(2):297\u2013306.","journal-title":"Circ Res"},{"issue":"7","key":"1581_CR33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","volume":"15","author":"Y Kameyama","year":"2005","unstructured":"Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-c) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15\u2009+\u2009C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513\u201322.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"1581_CR34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/clpt.2012.221","volume":"94","author":"Y Tomita","year":"2013","unstructured":"Tomita Y, Maeda K, Sugiyama Y. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther. 2013;94(1):37\u201351.","journal-title":"Clin Pharmacol Ther"},{"key":"1581_CR35","first-page":"e13","volume":"1","author":"J Lippert","year":"2012","unstructured":"Lippert J, Brosch M, von Kampen O, Meyer M, Siegmund HU, Schafmayer C, et al. A mechanistic, model-based approach to safety assessment in clinical development. CPT: Pharmacosmet Syst Pharmacol. 2012;1:e13.","journal-title":"CPT: Pharmacosmet Syst Pharmacol"},{"key":"1581_CR36","first-page":"e124","volume":"3","author":"RH Rose","year":"2014","unstructured":"Rose RH, Neuhoff S, Abduljalil K, Chetty M, Rostami-Hodjegan A, Jamei M. Application of a physiologically based pharmacokinetic model to predict OATP1B1-related variability in pharmacodynamics of rosuvastatin. CPT: Pharmacosmet Syst Pharmacol. 2014;3:e124.","journal-title":"CPT: Pharmacosmet Syst Pharmacol"},{"issue":"8","key":"1581_CR37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359(8):789\u201399.","journal-title":"N Engl J Med"},{"issue":"2","key":"1581_CR38","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","volume":"328","author":"T Watanabe","year":"2009","unstructured":"Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther. 2009;328(2):652\u201362.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1581_CR39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/clpt.2013.78","volume":"94","author":"X Chu","year":"2013","unstructured":"Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, et al. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther. 2013;94(1):126\u201341.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1581_CR40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jps.21802","volume":"99","author":"F Fenneteau","year":"2010","unstructured":"Fenneteau F, Poulin P, Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci. 2010;99(1):486\u2013514.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1581_CR41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1345\/aph.10177","volume":"35","author":"AJ Lee","year":"2001","unstructured":"Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 2001;35(1):26\u201331.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"1581_CR42","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1365-2125.1999.00066.x","volume":"48","author":"KR Yeo","year":"1999","unstructured":"Yeo KR, Yeo WW, Wallis EJ, Ramsay LE. Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. Br J Clin Pharmacol. 1999;48(4):610\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"436","key":"1581_CR43","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1080\/01621459.1996.10476708","volume":"91","author":"A Gelman","year":"1996","unstructured":"Gelman A, Bois F, Jiang J. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Am Stat Assoc. 1996;91(436):1400\u201312.","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"1581_CR44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10543400600851898","volume":"17","author":"F Jonsson","year":"2007","unstructured":"Jonsson F, Jonsson EN, Bois FY, Marshall S. The application of a Bayesian approach to the analysis of a complex, mechanistically based model. J Biopharm Stat. 2007;17(1):65\u201392.","journal-title":"J Biopharm Stat"},{"issue":"1","key":"1581_CR45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2193-9616-1-6","volume":"1","author":"M Krauss","year":"2013","unstructured":"Krauss M, Burghaus R, Lippert J, Niemi M, Neuvonen P, Schuppert A, et al. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silicon Pharmacol. 2013;1(1):6.","journal-title":"In Silicon Pharmacol"},{"issue":"2","key":"1581_CR46","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/clpt.2014.70","volume":"96","author":"B Wulkersdorfer","year":"2014","unstructured":"Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Muller M, Langer O. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Clin Pharmacol Ther. 2014;96(2):206\u201313.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1581-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-014-1581-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1581-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:31:14Z","timestamp":1747175474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-014-1581-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,2]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["1581"],"URL":"https:\/\/doi.org\/10.1007\/s11095-014-1581-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,2]]}}}